Clotiapine (Entumine) is an atypical antipsychotic[2] of the dibenzothiazepine chemical class.[3] It was first introduced in a few European countries (namely, Belgium, Italy, Spain and Switzerland), Argentina, Taiwan and Israel in 1970.[4]
Clinical data | |
---|---|
Trade names | Etumina, Etumine, Entumin, Etomine, Entumine |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, Intravenous and Intramuscular |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.016.512 |
Chemical and physical data | |
Formula | C18H18ClN3S |
Molar mass | 343.87 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Some sources regard clotiapine as a typical antipsychotic rather than atypical due to its high incidence of extrapyramidal side effects compared to the atypicals like clozapine and quetiapine, to which it is structurally related.[5] Despite its profile of a relatively high incidence of extrapyramidal side effects it has demonstrated efficacy in treatment-resistant individuals with schizophrenia according to a number of psychiatrists with clinical experience with it, some weak clinical evidence supports this view too.[4][5][6] A systematic review compared clotiapine with other antipsychotic drugs:
Summary | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
There was no evidence to support or refute the use of clotiapine in preference to other antipsychotic drug treatments for management of people with acute psychotic illness.[7] | ||||||||||||||||||||||||||||||||||||||||
|